NeuroMetrix Reports Q4 and Full Year 2023 Business Highlights
NeuroMetrix, Inc. (NURO)
Last neurometrix, inc. earnings: 4/20 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.neurometrix.com/investor-relations
Company Research
Source: GlobeNewswire
WOBURN, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2023. The Company's mission is to reduce the impact of neurological disorders and pain syndromes through innovative non-invasive medical devices. "Quell® Fibromyalgia growth accelerated in Q4 2023 reflecting the addition in Q3 2023 of two field business development managers and optimized clinical messaging. We also introduced direct-to-patient telemedicine capabilities, direct to physician sales, and reimbursement at select Veterans Administration (VA) facilities,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “Also, during Q4 2023 we achieved our goal of filing a premarket notification (510(k)) with the FDA to market Quell for chemotherapy induced peripheral neuropathy (CIPN). Quell received FDA breakthrough device designation for this indication in January 2022.” Dr. Gozani
Show less
Read more
Impact Snapshot
Event Time:
NURO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NURO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NURO alerts
High impacting NeuroMetrix, Inc. news events
Weekly update
A roundup of the hottest topics
NURO
News
- NeuroMetrix, Inc. (NASDAQ: NURO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NeuroMetrix, Inc. (NASDAQ: NURO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- NeuroMetrix, Inc.'s (NASDAQ:NURO) CEO Might Not Expect Shareholders To Be So Generous This Year [Yahoo! Finance]Yahoo! Finance
- NeuroMetrix names new independent director, terminates equity program; shares up [Seeking Alpha]Seeking Alpha
- NeuroMetrix Announces Steps Taken to Enhance Shareholder Value [Yahoo! Finance]Yahoo! Finance
NURO
Sec Filings
- 5/2/24 - Form 4
- 5/2/24 - Form 4
- 5/2/24 - Form 4
- NURO's page on the SEC website